Acute Late-Onset Diffuse Encephalopathy Secondary to Target Therapies in Metastatic Melanoma

Abstract

Immunotherapy and targeted therapies are both major drugs used for metastatic melanomas. Various severe adverse event are reported with both. Few cases of acute encephalopathy induced by targeted therapies are described, resolving after discontinuation, but it rarely occurs as a late adverse event. We report a severe acute late-onset diffuse encephalopathy induced by targeted therapy (BRAF and MEK inhibitors), not resolving after treatment discontinuation and immunosuppressive treatment.